Null IGF for the treatment of cancer

Details Null IGF for the treatment of cancer Null IGF for the treatment of cancer

2007-10-30

2007-10-30

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003100, C530S303000

Reexamination Certificate

active

09399120

ABSTRACT:
New methods for the treatment of cancer are provided. Null IGF (IGF variants with reduced receptor binding) is administered to subjects having cancer, thereby alleviating the symptoms of the cancer.

REFERENCES:
patent: 5187151 (1993-02-01), Clark et al.
patent: 5310742 (1994-05-01), Elias
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5473054 (1995-12-01), Jameson et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5643867 (1997-07-01), Maack et al.
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5723441 (1998-03-01), Higley et al.
patent: WO 95/03817 (1995-02-01), None
patent: WO 95/04076 (1995-02-01), None
patent: WO 95/13823 (1995-05-01), None
patent: 95/16703 (1995-06-01), None
patent: WO 96/02565 (1996-02-01), None
patent: WO 96/40722 (1996-12-01), None
patent: WO 97/39032 (1997-10-01), None
patent: 98/36764 (1998-08-01), None
Bayne et al. ‘The Role of Tyrosines 24, 31, and 60 in the High Affinity Binding of Insulin-Like Growth Factor-I to the Type 1 Insulin-Like Growth Factor Receptor’, Journal of Biological Chemistry, vol. 265, No. 26, Sep. 15, pp. 15648-15652.
Ngo et al., ‘Computational Complexity, Potein Structure Prediction, and the Levinthal Paradox,’ The Protein Folding Problem and Tertiary Structuer Prediction. Ed. K. Merz and L. Le Grand. BirkHauser, Boston MA. pp. 491-495. 1994.
Rudinger, J. (1976). Peptide Hormones (ed. J.A. Parsons). University Park Press. Baltimore. pp. 1-7.
Berendsen, Herman, “A Glimpse of the Holy Grail?”, Science, vol. 282, pp. 642-643, Oct. 23, 1998.
“Computerized Drug Design: Still Promising, Not Yet Here”, Science, vol. 256, pp. 441, Apr. 24, 1992.
Jain, Rakesh, Delivery of Molecular Medicine to Solid Tumors, Science, vol. 271, p. 1079-1080, Feb. 1996.
Dermer, Gerald. Anotehr Anniversary for the War on Cancer, Bio/Technolgoy, vol. 12, Mar. 1994.
Gura, Trisha. Systems for Identifying New Drugs are Often Faulty, Science, vol. 278, pp. 1041-1042. Nov. 1997.
Golden, Fredrick, Of Mice and Men: Don't Blame the Rodents, Time, pp. 44, May 18, 1998.
Adams et al., 1996, “Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey”Prog. Growth Factor Res. 6(2-4):347-356.
Ausubel et al., 1987,Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, (Table of Contents).
Baxter et al., 1986, “Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins”Biochem. Biophys. Res. Comm. 139(3):1256-1261.
Baxter et al., 1989, High molecular weight insulin-like growth factor binding protein complexJ. Biol. Chem. 264(20):11843-11848.
Baxter et al., 1992, “Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3”J. Biol. Chem.267:60-65.
Baxter, Robert C., 1988, “Characterization of the acid-labile subunit of the growth hormone-dependent insulin-like growth factor binding protein complex”J. Clin. Endocrinol. Metab. 67:265-272.
Bayne et al., 1990, “The roles of tyrosines 24,31, and 60 in the high affinity binding of insulin-like growth factor-I to the type 1 insulin-like growth factor receptor”J. Biol. Chem. 265:15648-15652.
Blum et al., 1991, “Plasma IGFBP-3 levels as clinical indicators”Modern Concepts in Insulin-like Growth Factors, E.M. Spencer, ed., Elsevier, New York, pp. 381-393.
Butler et al., 1998, “Stimulation of tumor growth by recombinant human insulin-like growth factor-I (IGF-I is dependent on the dose and the level of IGF-I receptor expression”Cancer Res. 58:3021-3027.
Cascieri et al., 1988, “Mutant of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor”Biochemistry27:3229-3233.
Cascieri et al., 1989, “Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors”J. Biol. Chem. 264(4):2199-2202.
Favoni et al., 1998, “Modulation of the insulin-like growth factor-I system byN-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines”Br. J. Cancer77(12): 2138-2147.
Giuliano et al., 1998, “Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors”Invest Ophthalmol. Vis. Sci. 39(8): 1300-1311.
Karas et al., 1997, “Membrane-associated insulin-like growth factor-binding protein-3 inhibit insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in Ishikawa endometrial cancer cells”J. Biol. Chem. 272(26):16514-16520.
Kelley et al., 1998, “Insulin growth factor-I inhibits apoptosis in hematopoietic progenitor cells”Ann. N. Y. Acad. Sci. 840: 518-524.
Leal et al., 1997, “The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein 3 receptor”J. Biol. Chem. 272(33):20572-20576.
Lee et al., 1995, “Purified rat acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in the absence of IGFs”Endocrinology136(11):4982-4989.
Nickerson et al., 1997, “Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells”.Biochem. Biophys. Res. Comm. 237:690-693.
Rajah et al., 1997, “Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism”J. Biol. Chem. 272(18):12181-12188.
Rinderknecht et al., 1976, “Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: Isolation, chemical characterization, and some biological properties of forms I and II”Proc. Natl. Acad. Sci. USA73(7):2365-2369.
Sambrook et al., 1989,Molecular Cloning: A Laboratory Manual, vols. 1-3 Cold Spring Harbor Laboratory Press, 2nd ed., (Table of Contents).
Sommer et al., 1991, “Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3”,Modern Concepts of Insulin-like Growth Factors, E.M. Spencer, ed., Elsevier, New York, pp. 715-728.
Toms et al., 1998, “Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-XL” J. Neurosurg. 88: 884-889.
Xu et al., 1997, “Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors”Br. J. Haematol. 97: 429-440.
Yang et al., 1996, “Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblats and rat glioma cells: Role of heparan sulfate proteoglycans”Endocrinology137(10):4363-4371.
Zadeh et al., 1997, “The 16-kDA proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene”Endocrinology138(7):3069-3072.
Zawada et al., 1998, “Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats”Brain Res. 786: 96-103.

Affiliated with

Also associated with

Rating

Null IGF for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Null IGF for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Null IGF for the treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3864333